Sun Ge, Zhuang Wei, Lin Qing-Tang, Wang Lei-Ming, Zhen Yu-Hang, Xi Sheng-Yan, Lin Xiao-Lan
Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.
Department of Neurosurgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.
World J Clin Cases. 2021 Apr 26;9(12):2845-2853. doi: 10.12998/wjcc.v9.i12.2845.
Glioblastoma is the most common type of brain tumor and is invariably fatal, with a mean survival time of 8-15 mo for recently diagnosed tumors, and a 5-year survival rate of only 7.2%. The standard treatment for newly diagnosed glioblastoma includes surgery followed by concurrent chemoradiotherapy and further adjuvant temozolomide. However, the prognosis remains poor and long-term survival is rare. This report aimed to demonstrate a new therapeutic strategy for the treatment of glioblastoma.
A patient was referred to the Department of Neurosurgery with an intracranial space-occupying lesion with a maximum diameter of approximately 5 cm. The tumor was compressing functional areas, and the patient accordingly underwent partial resection and concurrent chemoradiotherapy. The imaging and pathological findings were consistent with a diagnosis of glioblastoma with oligodendroglioma differentiation (World Health Organization IV). The patient was finally diagnosed with glioblastoma. However, the patient discontinued treatment due to intolerable side effects, and was prescribed Kangliu pill (KLP) 7.5 g three times/d, which he has continued to date. Significant shrinkage of the tumor (maximum diameter reduced from about 3.5 to about 2 cm) was found after 3 mo of KLP therapy, and the tumor was further reduced to about 1 cm after 3 years. The patient's symptoms of headache, limb weakness, and left hemiplegia were relieved, with no side effects.
KLP has been a successful intervention for glioblastoma, and the current case indicates that traditional Chinese medicine may offer effective alternative therapies for glioblastoma.
胶质母细胞瘤是最常见的脑肿瘤类型，无一例外都是致命的，最近诊断出的肿瘤平均生存时间为8 - 15个月，5年生存率仅为7.2%。新诊断胶质母细胞瘤的标准治疗包括手术，随后进行同步放化疗以及进一步的辅助替莫唑胺治疗。然而，预后仍然很差，长期生存极为罕见。本报告旨在展示一种治疗胶质母细胞瘤的新治疗策略。
一名患者因颅内占位性病变被转诊至神经外科，病变最大直径约5 cm。肿瘤压迫功能区，患者因此接受了部分切除术和同步放化疗。影像学和病理结果与伴少突胶质细胞瘤分化的胶质母细胞瘤（世界卫生组织IV级）诊断一致。患者最终被诊断为胶质母细胞瘤。然而，患者因无法耐受的副作用而停止治疗，并被开了康瘤丸（KLP），7.5 g，每日3次，至今一直在服用。KLP治疗3个月后发现肿瘤显著缩小（最大直径从约3.5 cm缩小至约2 cm），3年后肿瘤进一步缩小至约1 cm。患者的头痛、肢体无力和左侧偏瘫症状得到缓解，且无副作用。
康瘤丸对胶质母细胞瘤是一种成功的干预措施，当前病例表明中药可能为胶质母细胞瘤提供有效的替代治疗方法。
